iBio (NYSE:IBIO) shares rise more than 41% during post-market trading after providing an update on its COVID-19 toxicology study results and also announced the next-gen COVID-19 vaccine program.
The company said that its IND enabling toxicology studies testing IBIO-201 did not identify any adverse effects at low or high doses.
iBio also added that it continues to evaluate the potential of a multi-subunit vaccine candidate to further increase vaccine protection from variants by targeting two or more important elements of the SARS-CoV-2 virus.
IBIO stock is up 41.30% at $1.95 in the extended trading sessions.
On Wednesday, the stock was up 15% concluding litigation with Faunhofer US and enters into a license agreement.
Editor and Computer Expert
A hardcore tech enthusiast and computer expert Uson Abdilazhanov who holds a degree in communications started writing in his personal blogs since 2012. That time he was interested in the technical part of the computer. But now the software aspect plays an important role in his career. Currently, he runs a PC building and repairing shop which helps a lot of designers and gamers who always like to try new things.